Company Overview
Nexalin Technology, Inc. operates within the healthcare sector as a medical device company focused on the design and development of neurostimulation products intended for the treatment of mental health conditions in the United States and China. The company specifically markets Generation 1, an easy-to-administer medical device that utilizes bioelectronic medical technology to treat anxiety, distinguishing its product offerings within the specialized field of psychiatric care. Currently, the entity maintains a market capitalization of $7.50M and employs a workforce of 6 individuals to support its operational and development activities. The annual revenue generated over the trailing twelve months stands at $156,931, a figure that, when juxtaposed against a market capitalization of $7.50M, indicates a company operating on a micro-cap scale where asset valuation significantly exceeds current book value and revenue generation. This disparity between the high price-to-sales multiple and the modest revenue stream suggests that the market is pricing in future potential or specific technological advantages rather than current operational scale, highlighting the early-stage nature of the business model within the competitive medical device industry.
Financial Health
Over the trailing twelve months, Nexalin Technology reported a revenue of $156,931, while simultaneously recording a net income of $-8,678,910 and an EBITDA of $-8,833,284, revealing a substantial gap between top-line sales and bottom-line profitability that points to a heavy cost structure or significant one-time expenses. The company generated free cash flow of $-1,841,967, indicating a net cash outflow that limits immediate financial flexibility and suggests the business is consuming cash reserves to fund operations or development efforts. The gross margin stands at 69.5%, which demonstrates efficient production costs relative to sales, yet this is contrasted sharply by an operating margin of -12924.3% and a profit margin of 0.0%, figures that indicate severe operational inefficiencies or extreme expenses relative to the small revenue base. On the balance sheet, the company holds $4.35M in cash against N/A in debt, resulting in a debt-to-equity ratio of N/A, which implies a conservative capital structure free of traditional interest-bearing liabilities but reliant on equity financing. The current ratio is listed at 13.47, a metric that theoretically suggests strong short-term liquidity; however, in the context of negative net income and significant cash burn, this high ratio may reflect a liquidity position driven by low current liabilities rather than robust operational cash generation. Return on Equity is recorded at -178.5% and Return on Assets at -106.6%, metrics that reveal that management has not yet generated positive returns on the capital invested, reflecting the typical challenges faced by pre-profitable medical device firms in their developmental phases.
Valuation Assessment
The valuation metrics for Nexalin Technology show a trailing P/E ratio of N/A due to the lack of positive earnings, while the forward P/E is listed at -0.93, a negative figure that implies the market expects earnings to remain negative or for the company to continue operating at a loss in the near term. The price-to-book ratio stands at 1.39, indicating that the market values the company at 39% above its book value, a premium that investors may be assigning based on the proprietary nature of the neurostimulation technology despite current losses. Alternative valuation metrics include a price-to-sales ratio of 47.77 and an EV/EBITDA of -0.34, figures that suggest the stock is priced heavily relative to its sales volume and that the enterprise value relative to earnings is negative due to the lack of profitability. The stock has traded within a 52-week range bounded by a high of $2.57 and a low of $0.36, and without the current price explicitly listed in the provided facts, the valuation context is strictly defined by these historical extremes and the aforementioned multiples. The beta value is recorded at 4.10, a figure that signifies the stock is highly volatile and expected to fluctuate with much greater intensity than the broader market, reflecting the high risk associated with small-cap biotech and medical device companies.
Growth & Income
Nexalin Technology reported a revenue growth rate of -49.6% year over year, while the earnings growth rate is N/A due to negative earnings, a combination that implies the company is contracting in terms of top-line sales rather than expanding. Because the company reports a profit margin of 0.0% and net income of $-8,678,910, it is not a dividend payer, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company does not distribute cash to shareholders but instead retains its limited cash flows, which are currently negative at $-1,841,967, to reinvest into its research and development of neurostimulation products. The overall growth and income profile is characterized by significant revenue contraction and a complete lack of current profitability or dividend income, positioning the company as a high-risk, high-volatility entity with a beta of 4.10 that relies entirely on future product adoption and operational scaling to achieve financial sustainability.